{"id":"W4205675137","doi":"10.1007/s13555-021-00649-y","title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"LEO Pharma; Kyowa Hakko Kirin; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Quality of life (healthcare); Clinical trial; Medicine; Phase (matter); Quality (philosophy); Intensive care medicine; Internal medicine; Dermatology; Nursing; Philosophy; Physics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002504446,0.001035741,0.001731838,0.0003173,0.0003321841,0.0009158778,0.0005435412,0.001246798,0.002398631],"category_scores_gemma":[0.001136418,0.0003109975,0.001431805,0.0002830523,0.00045571,0.0006228912,0.0003181936,0.002045159,0.0003862583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005955716,"about_ca_system_score_gemma":0.0009418771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003512671,"about_ca_topic_score_gemma":0.001113263,"domain_scores_codex":[0.9991978,0.0004176905,0.00004311707,0.0001129719,0.00009030166,0.0001381461],"domain_scores_gemma":[0.9993446,0.0001121065,0.0001468308,0.00004693017,0.0000588488,0.0002905604],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8591464,0.03080531,0.004361241,0.001337951,0.001876876,0.000309185,0.0001400419,0.001424121,0.02268324,0.000306535,0.003810685,0.07379836],"study_design_scores_gemma":[0.7416344,0.2335528,0.01664112,0.00007231373,0.0006510427,0.0004433751,0.00003339156,0.001284305,0.002216932,0.0002914104,0.003140813,0.00003797225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870768,0.004785774,0.0005748895,0.0004779117,0.0001282389,0.003449084,0.001100829,0.0001133532,0.002293182],"genre_scores_gemma":[0.9877615,0.002354585,0.001274345,0.0008493271,0.0002069632,0.003513933,0.002006853,0.00001784753,0.00201457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002504446,"threshold_uncertainty_score":0.01324499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08333823224810268,"score_gpt":0.367916018610268,"score_spread":0.2845777863621653,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}